ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2023-3-1-59-65ppan-70Research ArticleCASE REPORTGeneralized Anxiety Disorder Therapy, Associated with Pronounced Side Effects, and Prospects for the Use of Pharmacogenetic Testing: Case reportStrelnikA. I.

Anna I. Strelnik

443016 Samara

Tel.: +79371770324

a.i.strelnik@samsmu.ruRomanovD. V.

Dmitriy V. Romanov

443016 Samara

StrelnikS. N.

Sergey N. Strelnik

443016 Samara

International Centre for Education and Research in Neuropsychiatry, Samara State Medical University; Department of Psychiatry, Narcology and Psychotherapy, Samara State Medical UniversityRussian FederationDepartment of Psychiatry, Narcology and Psychotherapy, Samara State Medical UniversityRussian Federation202317052023315965Copyright © Strelnik A.I., Romanov D.V., Strelnik S.N., 20232023Strelnik A.I., Romanov D.V., Strelnik S.N.Strelnik A.I., Romanov D.V., Strelnik S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/70

New generation antidepressants (AD) are widely used as first-line treatment for generalized anxiety disorder (GAD) and considered safely than tricyclics. Some side effects of AD are transient and may disappear after few weeks of treatment, but potentially severe may persist for a long time or occur later. Cardiovascular disorders (abnormal heart rhythm, QT prolongation, arterial hypertension, orthostatic hypotension) are especially dangerous side effects. Genetic polymorphisms of the enzymes involved in the metabolism of antidepressants may be one of the causes of side effects development. The objective of this case report is to demonstrate that timely assessment of the risk of side effects using pharmacogenetic testing (PGx) could have influenced choice of an antidepressant, timely dose adjustment, avoiding ineffective appointments. Use of the PGx can help to optimize GAD pharmacotherapy, its introduction into clinical practice requires further research.

pharmacogenetic testinggenetic polymorphismsantidepressantsside effectscardiac arrhythmiaarterial hypertensiongeneralized anxiety disorderReferencesTerlizzi, E.P.; Villarroel, M.A. Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019. NCHS Data Brief. 2020, 378, 1-8.Terlizzi, E.P.; Villarroel, M.A. Symptoms of Generalized Anxiety Disorder Among Adults: United States, 2019. NCHS Data Brief. 2020, 378, 1-8.DeMartini, J.; Patel, G.; Fancher, T.L. Generalized Anxiety Disorder. Ann Intern Med. 2019, 170(7), ITC49-ITC64. doi:10.7326/AITC201904020DeMartini, J.; Patel, G.; Fancher, T.L. Generalized Anxiety Disorder. Ann Intern Med. 2019, 170(7), ITC49-ITC64. doi:10.7326/AITC201904020Cipriani, A.; Furukawa, T. A.; Salanti, G.; Geddes, J. R.; Higgins, J. P.; Churchill, R.; Watanabe, N.; Nakagawa, A.; Omori, I. M.; McGuire, H.; Tansella, M.; Barbui, C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet 2009, 373(9665), 746–758. https://doi.org/10.1016/S0140-6736(09)60046-5Cipriani, A.; Furukawa, T. A.; Salanti, G.; Geddes, J. R.; Higgins, J. P.; Churchill, R.; Watanabe, N.; Nakagawa, A.; Omori, I. M.; McGuire, H.; Tansella, M.; Barbui, C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet 2009, 373(9665), 746–758. https://doi.org/10.1016/S0140-6736(09)60046-5Taylor, C.B. Depression, heart rate related variables and cardiovascular disease. Int J Psychophysiol. 2010, 78(1), 80-88. doi:10.1016/j.ijpsycho.2010.04.006Taylor, C.B. Depression, heart rate related variables and cardiovascular disease. Int J Psychophysiol. 2010, 78(1), 80-88. doi:10.1016/j.ijpsycho.2010.04.006Dobrodeeva, V.S.; Shnayder, N.A.; Nasyrova, R.F. Pharmacogenetic aspects of the efficacy and safety of trazodone therapy. Farmakogenetika i farmakogenomika 2019, 1, 25–28. (In Russ). DOI: 10.24411/2588-0527-2019-10038Dobrodeeva, V.S.; Shnayder, N.A.; Nasyrova, R.F. Pharmacogenetic aspects of the efficacy and safety of trazodone therapy. Farmakogenetika i farmakogenomika 2019, 1, 25–28. (In Russ). DOI: 10.24411/2588-0527-2019-10038Herbild, L.; Andersen, S.E.; Werge, T.; Rasmussen, H.B.; Jürgens, G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. 2013, 113(4), 266-272. doi:10.1111/bcpt.12093Herbild, L.; Andersen, S.E.; Werge, T.; Rasmussen, H.B.; Jürgens, G. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs? Basic Clin Pharmacol Toxicol. 2013, 113(4), 266-272. doi:10.1111/bcpt.12093

The authors declare that there are no conflicts of interest present.